Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Aastrom's Dendritic Cell Vaccine Technology to be Utilized in Duke University's Clinical Trial for New Cancer Treatment
-- Duke Clinical Trial Seeks New Treatment for GI Tract Cancers --
View HTML
Toggle Summary Aastrom Biosciences Holds Investor Conference Call Today
Aastrom Biosciences Holds Investor Conference Call Today Ann Arbor, Michigan, November 14, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) will hold an investor call today, November 14, 2003 at 10:00 a.m. EST. The purpose of the call is to bring shareholders and other interested parties
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, November 12, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it will hold an investor conference call on Friday, November 14, 2003 at 10:00 a.m. EST. The purpose of the call will be to bring
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports First Quarter 2004 Financial Results
-- Company Prepares to Enter Clinical Trials of Bone Graft Product --
View HTML
Toggle Summary Aastrom Biosciences Launches Direct Stock Purchase Program
-- Program Offers Shareholders Exclusive Investment Opportunity --
View HTML
Toggle Summary Aastrom Biosciences to Present at Fifth Annual Rodman & Renshaw Techvest Healthcare Conference
Aastrom Biosciences to Present at Fifth Annual Rodman & Renshaw Techvest Healthcare Conference Ann Arbor, Michigan, October 17, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that its President and CEO, R. Douglas Armstrong, Ph.D., will present at the Fifth Annual Rodman &
View HTML
Toggle Summary Herbert S. Schwartz, M.D. Appointed to Aastrom Biosciences' Technology Review Board
Herbert S. Schwartz, M.D. Appointed to Aastrom Biosciences' Technology Review Board Ann Arbor, Michigan, October 14, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced the appointment of Herbert S. Schwartz, M.D. to its Technology Review Board (TRB). Dr.
View HTML
Toggle Summary Aastrom Biosciences Receives NIH Grant to Develop Stem Cell Treatment for Diabetic Circulation Disorders
-- Study Marks Aastrom's Entry into Vascular Regeneration Marketplace --
View HTML
Toggle Summary Aastrom Biosciences Receives NIH Grant for Dendritic Cell Vaccine Research
-- Study Expands Aastrom's Tumor Antigen Primed Vaccine Approach to Ovarian Cancer --
View HTML
Toggle Summary Aastrom Biosciences Receives FDA Approval to Initiate Multi-Center Clinical Trial for Bone Graft Product
-- IND Approval Key Milestone for Aastrom's Stem Cell Product Program for Tissue Generation --
View HTML